Although further studies are required in tau models, especially to establish a dose–response relationship, our study, which shows that levetiracetam failed at decreasing neurofibrillary tangles and improving cognition in a tau model, could explain why the levetiracetam treatment of AD patients did not reach efficacy in cognitive outcomes. This evidence concerns the gene MAPT and Alzheimer disease.